Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte (Q73245479)

From Wikidata

Jump to navigation Jump to search

scientific article published on 01 October 1999

Language	Label	Description	Also known as
English	Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte	scientific article published on 01 October 1999

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586336%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586336%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

follicular lymphoma

1 reference

based on heuristic

inferred from title

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586336%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

author name string

B Coiffier

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586336%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

E M Neidhardt-Bérard

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586336%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

H Tilly

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586336%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

C Belanger

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586336%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

R Bouabdallah

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586336%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

P Brice

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586336%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

P Y Péaud

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586336%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

J L Pico

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586336%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

M Janvier

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586336%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

P Solal-Celigny

11

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586336%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

N Brousse

12

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586336%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 October 1999

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586336%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Annals of Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586336%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586336%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

10

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586336%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

1191-1197

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586336%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008347425795

7 January 2021

based on heuristic

inferred from DOI database lookup

Recombinant interferon alfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. Groupe d'Etude des Lymphomes de l'Adulte

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008347425795

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of interferon alfa-2b in the induction and maintenance treatment of low-grade non-Hodgkin's lymphoma: results from a prospective, multicenter trial with double randomization

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008347425795

7 January 2021

based on heuristic

inferred from DOI database lookup

Doxorubicin-containing regimen with or without interferon alfa-2b for advanced follicular lymphomas: final analysis of survival and toxicity in the Groupe d'Etude des Lymphomes Folliculaires 86 Trial.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008347425795

7 January 2021

based on heuristic

inferred from DOI database lookup

Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008347425795

7 January 2021

based on heuristic

inferred from DOI database lookup

Fludarabine, mitoxantrone, and dexamethasone: an effective new regimen for indolent lymphoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008347425795

7 January 2021

based on heuristic

inferred from DOI database lookup

A new serologic staging system for large-cell lymphomas based on initial beta 2-microglobulin and lactate dehydrogenase levels

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008347425795

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1023/A:1008347425795

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586336%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10586336%20AND%20SRC:MED&resulttype=core&format=json

2 November 2019

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q73245479&oldid=1947011082"